trending Market Intelligence /marketintelligence/en/news-insights/trending/awysos28osyijjk2kxfc-g2 content esgSubNav
In This List

BTG emphysema treatment rejected by US FDA

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


BTG emphysema treatment rejected by US FDA

BTG plc said the U.S. Food and Drug Administration denied premarket approval for its Elevair Endobronchial Coil System.

Elevair uses a procedure in which metal coils are placed into the lungs of patients with severe emphysema. The treatment, branded outside the U.S. as the RePneu Coil System, is a product of BTG's California-based unit PneumRx Inc.

The regulator's anesthesiology and respiratory therapy devices panel voted against Elevair's approval in June, questioning its efficacy.

The London-based company said it is reviewing its options.

Emphysema, which affects an estimated 3.5 million adults in the U.S., causes breathlessness, labored breathing and eventual respiratory failure.

BTG develops and sells pharmaceutical products through three segments — interventional medicine, pharmaceuticals and licensing.